Table 4.
Complications, treatments, and clinical outcomes in patients with adenovirus-associated ARDS.
| Characteristic | Adenovirus associated ARDS (n = 14) | Non-adenovirus associated ARDS (n = 33) | P-value |
|---|---|---|---|
| Complications | |||
| AKI | 10(71.43%) | 13(39.39%) | 0.045 |
| Sepsis shock | 4(28.57%) | 12(36.36%) | 0.86 |
| Pneumothorax | 2(14.29%) | 0 | 0.02 |
| Treatments | |||
| CRRT | 6(42.86%) | 10(30.30%) | 0.62 |
| ECMO | 3(21.43%) | 2(6.06%) | 0.30 |
| Prone position ventilation | 1(7.14%) | 2(6.06%) | 0.89 |
| Vasoactive | 11(78.57%) | 25(75.76%) | >0.99 |
| Muscle relaxants | 11(78.57%) | 20(60.61%) | 0.39 |
| Intravenous immune globulin | 6(42.86%) | 10(30.30%) | 0.62 |
| Anti-viral agents | |||
| Oseltamivir | 7(50.00%) | 11(33.33%) | 0.28 |
| Ganciclovir | 11(78.57%) | 9(27.27%) | 0.001 |
| Clinical outcomes | |||
| Duration of dyspnea to IMV | 1.00(1.00-2.00) | 3.00(2.00-5.00) | >0.99 |
| Duration of IMV (days) | 22.00(14.00-75.25) | 22.00(10.00-34.00) | 0.41 |
| Length of ICU stay(days) | 26.50(15.75-75.25) | 27.00(11.50-41.50) | 0.52 |
| Length of hospital stay(days) | 37.50(29.75-81.00) | 46.00(27.50-57.50) | 0.89 |
| Death | 2(14.29%) | 4(12.12%) | >0.99 |